Trial · NCT03852719
Adverse events720
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 720
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Delayed Treatment (Baseline to Week 48) | 3 | 51 | |
| other | Anaemia | Blood and lymphatic system disorders | Bulevirtide 2 mg/Day (Baseline to Week 48) | 3 | 49 | |
| other | Anaemia | Blood and lymphatic system disorders | Bulevirtide 10 mg/Day (Baseline to Week 48) | 2 | 50 | |
| other | Anaemia | Blood and lymphatic system disorders | Bulevirtide 2 mg/Day (Baseline to Week 144) | 5 | 49 | |
| other | Anaemia | Blood and lymphatic system disorders | Bulevirtide 10 mg/Day (Baseline to Week 144) | 3 | 50 | |
| other | Anaemia | Blood and lymphatic system disorders | Delayed Treatment/Bulevirtide 10 mg/Day (Week 48 to Week 144) | 3 | 50 | |
| other | Anaemia | Blood and lymphatic system disorders | Bulevirtide 2 mg/Day (After EOT (>Week 144 up to Week 240)) | 1 | 46 | |
| other | Anaemia | Blood and lymphatic system disorders | Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) | 1 | 47 | |
| other | Anaemia | Blood and lymphatic system disorders | Delayed Treatment/Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) | 5 | 49 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Delayed Treatment (Baseline to Week 48) | 0 | 51 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Bulevirtide 2 mg/Day (Baseline to Week 48) | 5 | 49 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Bulevirtide 10 mg/Day (Baseline to Week 48) | 5 | 50 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Bulevirtide 2 mg/Day (Baseline to Week 144) | 5 | 49 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Bulevirtide 10 mg/Day (Baseline to Week 144) | 5 | 50 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Delayed Treatment/Bulevirtide 10 mg/Day (Week 48 to Week 144) | 1 | 50 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Bulevirtide 2 mg/Day (After EOT (>Week 144 up to Week 240)) | 0 | 46 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) | 0 | 47 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Delayed Treatment/Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) | 0 | 49 | |
| other | Leukopenia | Blood and lymphatic system disorders | Delayed Treatment (Baseline to Week 48) | 10 | 51 | |
| other | Leukopenia | Blood and lymphatic system disorders | Bulevirtide 2 mg/Day (Baseline to Week 48) | 7 | 49 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03852719/events